Sen-Jam Pharmaceutical Welcomes Immunology and Infectious Disease Expert Dr. Ashley St. John to its Scientific Advisory Board

HUNTINGTON, N.Y., March 11, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical is thrilled to announce the appointment of Dr. Ashley St. John, Ph.D., to its Scientific Advisory Board, further strengthening its commitment to pioneering next-generation, inflammation-modulating therapies.

Dr. St. John is a tenured Associate Professor at Duke-National University of Singapore (Duke-NUS) Medical School, where she leads the Laboratory of Immunity and Immune Pathology within the Program in Emerging Infectious Diseases. An internationally recognized expert in immunology, host-pathogen interactions, and vaccine development, she has published extensively on mast cell biology, viral immunity, and novel therapeutic strategies.

Her research, which has been featured in top-tier journals such as Nature Reviews Immunology, The Journal of Clinical Investigation, and Science Advances, has been instrumental in shaping modern approaches to immune modulation and inflammation control. She has also been at the forefront of mucosal vaccine research, AI-driven drug discovery, and next-generation therapeutics, areas that closely align with Sen-Jam Pharmaceutical's PAIR (Pleiotropic Anti-Inflammatory Regulators) technology.

Expressing her enthusiasm for joining Sen-Jam, Dr. St. John stated: "I am excited to collaborate with Sen-Jam Pharmaceutical as they challenge the status quo in inflammation science. Their novel approach to immune modulation and drug development is particularly timely, as we continue to uncover the pivotal role inflammation plays in a wide range of diseases. I look forward to contributing my expertise in immunology and host-pathogen interactions to help advance Sen-Jam's transformative mission."

Jim Iversen, CEO of Sen-Jam Pharmaceutical, shared: "Dr. St. John's groundbreaking work in immunology and infectious disease research brings unparalleled value to Sen-Jam. As we advance our lead assets, including SJP-005 for non-opioid relief for opioid withdrawal and SJP-002C for viral respiratory infections, her expertise will be instrumental in optimizing our scientific and clinical strategies. We are honored to have her on board as we continue our mission to develop proactive, pre-emptive solutions for inflammation-driven conditions."

Jackie Iversen, Co-Founder & Chief Clinical Officer of Sen-Jam Pharmaceutical, also shared her excitement: "Ashley's deep expertise in immunology and infectious diseases makes her an incredible asset to our Scientific Advisory Board. Her passion for translating scientific discoveries into real-world solutions aligns perfectly with our mission to bring fast, safe, and accessible therapeutics to patients. We are honored to have her on this journey with us"

Please join us in welcoming Dr. Ashley St. John to the Sen-Jam Pharmaceutical family!

About Sen-Jam Pharmaceutical
Sen-Jam Pharmaceutical is at the forefront of inflammation-modulating drug development, pioneering PAIR (Pleiotropic Anti-Inflammatory Regulators) technology to prevent and mitigate inflammation at its source. With a growing portfolio targeting alcohol hangover prevention, viral respiratory infections, opioid withdrawal, and chronic inflammatory conditions, Sen-Jam is reimagining the pharmaceutical landscape—shifting from reactive treatments to proactive health preservation.

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
[email protected]

SOURCE Sen-Jam Pharmaceutical